The aim of this study was to determine whether creatinine clearance can be estimated as well by clearance of gentamicin/tobramycin as by routine, non-invasive estimates in the intensive care unit.
Renally cleared drugs with narrow therapeutic margins need to be given in reduced doses for patients with renal impairment. For many such drugs (e.g. vancomycin, digoxin, gentamicin and tobramycin), dosing is guided by therapeutic drug monitoring. However, some drugs are not routinely assayed and for these (e.g. aciclovir, ganciclovir, gabapentin and pregabalin) dosage modifications are based upon estimates of renal function (creatinine clearance [CrCl] or glomerular filtration rate [GFR] ).
There are several ways of estimating CrCl/GFR but for practical purposes in the intensive care unit (ICU), these are limited to timed urine collections with mid-point blood sampling, the Cockroft-Gault (C&G) 1 or Modification of Diet in Renal Disease (MDRD) equations 2, 3 . Administering exogenous compounds (e.g. Inulin, 51 Cr-EDTA, 125 I-iothalamate or 99m Tc-DTPA) to estimate GFR cannot be justified in routine ICU practice, especially for drug dose modification where knowing the exact level of renal function is not necessary, though it is important to know approximately how impaired renal function is 4 . Because renal function can change rapidly in ICU patients, timely estimates of renal function are needed if they are to be of any assistance in guiding drug dosing.
Accuracy of urine collections are problematic in ambulant patients 5 , but this should not be a problem for catheterised ICU patients. Shorter timed collections have been found by some 6, 7 to be a good approximation of the 24-hour value in catheterised ICU patients, but this is not a universal finding 8 .
Estimating renal function via the concentration of endogenous substances is complicated because the concentration in blood depends upon both production and clearance of the substance. The relative proportions of fat (and other non-creatinine producing tissues) and muscle is important. While the original C&G equation used actual body weight (comparing it to a 72 kg standard), using lean body weight (LBW) reduces over-estimates in obese patients [9] [10] [11] . Cachexia poses similar problems which may be reduced by using a minimum creatinine concentration to limit overestimation in C&G calculations 6, 9, 12 .
The original MDRD equation 2 incorporates six patient variables (albumin, blood urea nitrogen, creatinine, age, gender and race) (denoted herein as MDRD6) while the 'simplified' MDRD equation 3 incorporates only the latter four variables (denoted herein as MDRD4). other modifications have been suggested 13 , but these equations are primarily intended to diagnose renal impairment 14 rather than to guide drug dosages. Earlier limitations (i.e. values be reported only when ≤60 ml/min/1.73 m 2 ) have now been relaxed (report if ≤90 ml/min/1.73 m 2 ) and some advocate using these equations for drug dosage modification where "no other measure of GFR is known" 13 . In order to use MDRD estimates for particular patients, the reported value should be corrected for body surface area (BSA) by another equation incorporating body weight and height 15 .
Another endogenous substance, Cystatin C (CysC), has been recommended as a tool for estimating CrCl/GFR. CysC is produced at a constant rate by nucleated cells and has minimal tubular secretion and non-renal clearance 16 , properties that suggest it should be an excellent marker of renal function. Some studies support 17, 18 though others have questioned this 19 . At this time, estimating CrCl/ GFR via CysC has not been widely adopted, partly for assay-related reasons but also for other reasons 18 , including altered CysC concentrations in hyper-and hypothyroidism and with high-dose corticosteroid use 16 .
Aminoglycosides might be used to estimate renal function because they are freely filtered, neither secreted or reabsorbed in the kidney and have little non-renal clearance. Studies comparing aminoglycoside clearance to estimates of CrCl in ICU patients have been conflicting, finding either good 9, 20, 21 or poor correlation 22 . Studies comparing aminoglycoside clearance with other non-invasive estimates of renal function used in the ICU have not been recently conducted. We therefore compared estimates of CrCl/GFR including MDRD4 and MDRD6 equations, C&G equation, two equations utilising CysC concentration and two timed urine collections with an estimate (gentamicin clearance [GentCl]) based upon gentamicin/tobramycin clearance.
MATERIAlS AND METHoDS
Patients prescribed gentamicin or tobramycin for a therapeutic reason in the 14-bed medical/surgical ICU of The Queen Elizabeth Hospital were eligible. A 'convenience sampling' strategy was adopted whereby patients were enrolled primarily when the principal author was available, typically five days/ week. Ethics Committee approval was obtained and the study conducted in accordance with the Declaration of Helsinki. Additional inclusion criteria were: intravenous access, indwelling urinary catheter and planned stay in the ICU for >24 hours. Cimetidine or trimethoprim prescription and any form of dialysis were exclusion criteria.
The dose of gentamicin/tobramycin was determined by the caring intensivist according to routine ICU practice. Gentamicin/tobramycin was administered over 30 minutes (computerised pump) and the first blood sample taken ≥30 minutes later. The second sample was taken at a time estimated to be ≥2×t1/2 later. These blood samples were also used (for creatinine concentration) in the calculations of creatinine clearance from the timed urine collections. The two-hour urine collection was commenced when the aminoglycoside infusion started and the 24-hour collection commenced at the end of the two-hour collection. Times were recorded to the nearest five minutes by the caring registered nurse. Patient age and weight were obtained from the patient, relatives and/or clinical notes. When actual body weight was unavailable, the registered nurse and study pharmacist estimated LBW from visual inspection of the patient. Height was measured by tape measure on the supine patient if not available from the patient or case-notes.
Equations used to estimate CrCl/GFR are listed in the Appendix. GentCl was derived by comparing calculated gentamicin / tobramycin clearance (calculated by back extrapolation of the decay curve to derive concentration at time 0 [C 0 ] and then volume of distribution [Vd]) with a 'normal' value of 83 ml/min. After 30 patients were enrolled, the responsible intensivist was provided with the panel of available estimates (C&G, MDRD4, MDRD6, two-and 24hour urine collections and GentCl) and asked for an 'expert opinion' of CrCl/GFR based upon their awareness of the patient. This was used as one comparator.
DATA CoMPARISoN
All estimates of CrCl/GFR were compared against two comparators (viz the 'expert opinion' and 24-hour urine estimate) using both standard regression and a cumulative distribution of difference. Values falling within 10 and 20% of the comparator were considered a good reflection, while those that were >50% distant were considered a poor reflection of the comparator. A non-parametric test (Kolmogorov-Smirnov) was used to compare estimates with the comparator and a P value of ≤0.05 was used to denote statistical significance. Comparisons were made between estimates for the whole study population and for those patients whose MDRD4 estimate was ≤60 ml/min/1.73 m 2 .
on the standard regression comparisons, the slope of the line shows the bias of the estimate (slope=1 when no bias). The width of the prediction interval shows the variability across the data relative to the comparator and the smaller the value, the higher the precision. The estimates are arranged such that those that are logically the most similar are adjacent (viz equation estimates are adjacent, urine collection derived estimates are adjacent etc).
RESULTS
one hundred patients were enrolled over 16 months to February 2007. Demographics including estimated LBW, age, gentamicin dose and estimated C 0 are given in Table 1 . Gentamicin was given to 87 patients and tobramycin to 13.
There was a large variability in Vd and a higher than anticipated mean value (0.31 l/kg) ( Table 1) . More than two-thirds of the patients had a Vd >0.25 l/kg and >40% had a Vd >0.3 l/kg.
The mean values for the various estimates of CrCl/GFR were higher than expected (76 to 122 ml/minute). The mean two-hour urine estimate (122 ml/minute) was significantly higher (P=0.004) than the 24-hour urine estimate (92 ml/minute) and CrCl=creatinine clearance, GFR=glomerular filtration rate, C&G=Cockroft-Gault. P values are for a Kolmogorov-Smirnov test, which tests whether the distributions of the test results by the two methods can reasonably be assumed to be identical. Slope is the slope of the regression of the standard method on the alternative method -the closer to 1 the better. PI width is the width of the prediction interval of the standard method for a patient by the alternative method -the smaller the better. The three percentage columns show the percentage of patients within or outside the given percentage of the standard method when assessed by the alternative method. The P value is the significance level of the Kolmogorov-Smirnov test of the standard method and the alternative method.
also higher than all other estimates of GFR/CrCl (Table 2) . Using the 'expert opinion' as comparator for all patients, the GentCl estimate performed best, being within 10% of the value on 44% of occasions and within 20% on 78% of occasions (Table 3 and Figure 1 ). This estimate was also least likely (6%) to be >50% outside the 'expert opinion'. of the other estimates, only the two-hour urine (P <0.001), 24-hour urine (P=0.01) and MDRD4 estimate (P=0.01) were statistically different to the 'expert opinion' (Table 3) .
Using the 24-hour urine estimate as comparator for all patients, the GentCl estimate was within CrCl=creatinine clearance, GFR=glomerular filtration rate, GentCI=gentamicin clearance, C&G=Cockroft-Gault. P values are for a Kolmogorov-Smirnov test, which tests whether the distributions of the test results by the two methods can reasonably be assumed to be identical. Slope is the slope of the regression of the standard method on the alternative method -the closer to 1 the better. PI width is the width of the prediction interval of the standard method for a patient by the alternative method -the smaller the better. The three percentage columns show the percentage of patients within or outside the given percentage of the standard method when assessed by the alternative method. The P value is the significance level of the Kolmogorov-Smirnov test of the standard method and the alternative method. 10% of the value on 14% of occasions and within 20% on 39% of occasions (Table 3 and Figure 1 ). While not as good using this comparator, the GentCl estimate was within 20% of the comparator at least as often as other estimates and less likely to be >50% distant. The C&G estimate appeared to outperform the MDRD4 estimate using either comparator. Few patients had an MDRD4 estimate of CrCl/ GFR ≤60 ml/min/1.73 m 2 (Table 4 ) and as a consequence, none of the estimates were statistically different from either comparator. Perhaps the best estimate in this population was the GentCl.
Twenty-six patients had an 'expert opinion' CrCl in the range of 80 to 120 ml/min and the mean of the GentCl estimates values in this cohort was 80.1 ml/min. This value was very similar to the chosen 83 ml/min used as a reference.
Relationships between the two comparators and each of the estimates for the whole population are shown in Figures 3 and 4 . Using the 'expert opinion' as comparator, the C&G outperformed both MDRD estimates (slope and prediction interval width) for the whole population (Figure 3 ). This graphic also shows that the GentCl was at least as good as any other estimate and better than most. Using the 24-hour urine estimate as comparator, the C&G and MDRD6 estimates outperformed the MDRD4 estimates and the GentCl estimate was at least as good as all other estimates (Figure 4 ).
DISCUSSIoN
The CysC and MDRD equations provide estimates of GFR (rather than CrCl) and since creatinine is partly secreted via the kidneys, these estimates should be lower than CrCl based estimates (viz C&G, two-and 24-hour urine estimates). There is some evidence for this in these data because the mean values of CysC based estimates and MDRD6 estimate were lower than both urine estimates and the C&G estimate ( Table 2) . The difference between GFR and CrCl would not be expected to be evident at this level of renal function however, because it is only at lower levels that secretion becomes an important portion of total elimination. Since both CrCl and GFR are used interchangeably in the ICU, no attempt was made to adjust the results to allow for creatinine secretion. From a clinical perspective in the ICU, an estimate of renal function needs to approximate the actual CrCl as often as possible and be wildly 'off the mark' as infrequently as possible. For most situations, being within 20% of actual CrCl is acceptable and >50% removed is unacceptable. Using these criteria, the GentCl estimate was arguably the best overall in this study, with the C&G arguably being the best of the equation estimates.
The MDRD4 estimate appeared inferior to both C&G and MDRD6 estimates in this study. This finding is very similar to that from an earlier study 24 of patients with chronic kidney disease but relatively normal serum creatinine (mean GFR 109 ml/min/1.73 m 2 ) where both MDRD estimates were found to be less accurate than the C&G estimate. This was also the finding from another study comparing several equation-based estimates with a 99m Tc-DTPA estimate in subjects with a normal creatinine concentration 11 . The MDRD6 estimate outperformed the MDRD4 in the current study, which is of interest because the latter has virtually replaced the MDRD6 and because of the expanding recommendations, viz to quote the GFR value when the MDRD4 estimate is ≤90 ml/min/1.73 m 2 and to use for drug dose calculations if no other estimate is available 13 . our data do not support using the MDRD4 equation in the ICU and since neither equation outperformed the C&G, both are more complicated and need correction for BSA, we do not recommend either be used in the ICU.
one reason for the apparent inferiority, relative to the C&G, of the MDRD estimates in the current study may be our study design where both MDRD equations were 'converted' (by BSA) for each patient. The reverse was applied in the original study comparing the MDRD6 to C&G estimates 2 . Any error in BSA calculation would affect the CrCl estimate that is converted but since the MDRD estimate must be 'converted' for each patient before it can be applied in clinical practice, our design is clinically more appropriate.
The 'expert opinion' used in this study was provided by six ICU physicians, each armed with a panel of six estimates of GFR/CrCl and intimately aware of the patients' clinical status (including fluid status, blood pressure, vasopressor use etc.).
Reasons that one or other of the estimates might be suspect (e.g. low urine volume) were made known to the intensivist. There was potential for different processes/emphases to be used and a possibility that an 'averaging' process would occur such that the 'expert opinion' may be closer to the middle ground of all the estimates. However, the mean value of the 'expert opinion' is very close to the GentCl estimate and at the lower end of the range of estimates. It appears likely therefore either the intensivists were biased in favour of the GentCl estimate or that it was a more accurate estimate of CrCl/GFR. Since none of the intensivists were directly involved in the study, the latter explanation appears more likely.
The two-hour urine estimate was inferior to the 24-hour estimate, being >50% removed from the value almost as often as it was within 20% (Table 3) . CrCl estimates from timed urine collections have previously been noted to be imperfect in studies comparing them to exogenous markers of GFR including inulin 6, 9, 25 and 125 I-iothalamate 2, 26 . Timed estimates are limited by factors including inaccurate urine collections (especially in ambulant patients) 5, 27 and it has been observed that repeated studies in the same patients can result in clinically significant differences 5 . The present study was performed in catheterised patients (and accuracy of urine collection was assured) but the findings suggest the two-hour urine collection method should not be used to estimate CrCl in the ICU.
GentCl has previously been shown to be a better estimate of CrCl than the 24-hour urine estimate in a study using inulin as the comparator 9 . We do not recommend giving aminoglycosides merely to estimate renal function however, and in patients not receiving aminoglycosides for a therapeutic purpose, the 24-hour urine method remains the most practical estimate of CrCl.
As reported previously 9, 12, 20, [28] [29] [30] 32 , the mean gentamicin Vd in ICU patients was >0.25 l/kg and given the variability (0.18 to 0.71 l/kg) and that 40% had a Vd >0.3 l/kg, it would appear prudent to assume a Vd of at least 0.3 l/kg until the actual value is known. Increases in Vd have been reported before in association with clinical situations including sepsis 12, [31] [32] , though this is not a consistent finding 29 .
lIMITATIoNS oF THE STUDY
The lack of a true gold standard estimate of renal function limits comparisons with each of the estimates. Several gold standard methods have been published but they are not necessarily equal. Inulin has been the traditional gold standard and it has been shown by some to be better than 99m Tc-DTPA, 125 I-iothalamate and iohexol 18 . There are also data suggesting different values can result when >1 gold standard method is used 26 . In the absence of a true gold standard, the best estimate of renal function is likely to come from a panel of differently derived estimates because this increases the likelihood that any one, flawed estimate would be excluded. Conversely, if all estimates in the panel of differently derived estimates were similar, it increases the likelihood that the estimate is close to the true value. We therefore believe that the 'expert opinion' used in this study is a reasonable comparator against which other estimates could be compared. In typical ICU practice, administering exogenous substances merely to derive an estimate of renal function is not justifiable, and hence our study showing that GentCl is at least as good as the other estimates should allow earlier and better estimates of renal function to be available.
These findings should be used with caution in patients with severe renal dysfunction. The mean CrCl/GFR estimates in the current study were >70 ml/minute and few had CrCl/GFR estimates <60 ml/minute -indeed, only six had an estimate <30 ml/minute.
The first blood sample was drawn ≥30 minutes after the end of the (30 minute) infusion but there are data suggesting the distribution half-life is approximately 30 minutes, especially when larger doses are administered [33] [34] [35] . If true, the estimates for maximum concentration in this study could be falsely elevated and consequently Vd estimates falsely lowered. However, since the mean value for Vd was larger than expected, we think this period was sufficient for distribution to occur in this study where the mean dose was 3.5 mg/kg (LBW) given over ≥30 minutes and the mean time to first blood sample was 0.54 hours. Importantly, the GentCl estimate was at least as good as the best alternative estimate and we are therefore confident that the 30-minute period was adequate.
CoNClUSIoNS
Estimating CrCl via aminoglycoside clearance is easily performed and provides an estimate that is at least as good as traditionally used, non-invasive methods in the ICU. Because aminoglycoside concentrations should be monitored to ensure antimicrobial efficacy, the CrCl estimate is a 'bonus' that can assist the dosing of other renally-cleared drugs. The GentCl estimate is also available sooner than the 24-hour urine method which increases the clinical value of this estimate.
